INNOVIVE Pharmaceuticals, Inc. today announced the presentation of additional data from its clinical and preclinical evaluation of the company’s drug candidates INNO-406, an orally bioavailable dual Bcr-Abl and Lyn-kinase inhibitor for Gleevec -resistant or intolerant chronic myelogenous leukemia, and INNO-305, a peptide immunotherapy for the treatment of acute myelogenous leukemia.
Pro-vitamin E Shown To Be Active Against Breast Cancer Cells
A precursor of vitamin E has been shown to be effective against breast cancer cell lines which over-express human epidermal growth factor receptor (HER2).About 30% of breast cancers exhibit high levels of HER2 - a feature that appears to make the disease resistant to many common treatments including chemotherapeutic agents. [click link for full article]
Vitamin E precursor effective against breast cancer cells
Washington, Dec 9 (ANI): A new study by researchers at Griffith University's School of Medical Science, Australia, has found that a precursor of vitamin E is effective against breast cancer cell lines which over-express human epidermal growth factor receptor (HER2). About 30 percent of breast cancers exhibit high levels of HER2 - a feature that appears to make the disease resistant to many